Pfizer (PFE)
(Delayed Data from NYSE)
$29.42 USD
-0.24 (-0.81%)
Updated Sep 20, 2024 04:01 PM ET
After-Market: $29.40 -0.02 (-0.07%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Price, Consensus and EPS Surprise
PFE 29.42 -0.24(-0.81%)
Will PFE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PFE
Here's Why Pfizer (PFE) Fell More Than Broader Market
Roche Antiviral Drug Reduces Transmission in Late-stage Study
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
Other News for PFE
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
EU pharma committee takes positive view on AbbVie, Merck, others
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Pfizer/BioNTech new COVID shot endorsed by EMA advisory panel
Pfizer, BioNTech announce CHMP recommendation for COVID-19 vaccine